TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34904647

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional wound dressing
Number of subjects: 100
Study: 33992292

Group type: EXPERIMENTAL
Intervention: Music-based physical therapy
Number of subjects: 13
Study: 35063953

Group type: EXPERIMENTAL
Intervention: As-needed low-dose combination budesonide-formoterol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Maintenance inhaled corticosteroids (ICS)
Number of subjects: 74
Study: 33591613

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 35627855

Group type: EXPERIMENTAL
Intervention: Robotic therapy (30 min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional therapy (30 min)
Number of subjects: 26
Study: 34521400

Group type: EXPERIMENTAL
Intervention: Mobile-app-based instruction coupled with routine cares
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine cares
Number of subjects: 64
Study: 35093240

Group type: EXPERIMENTAL
Intervention: SY-004 (2 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SY-004 (20 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SY-004 (40 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SY-004 (80 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SY-004 (120 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (20 mg, 40 mg, 80 mg, 120 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: SY-004 (all doses)
Number of subjects: 44
Study: 33579857

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stretching-and-toning (SAT)
Number of subjects: 70
Study: 35640767

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 34641918

Group type: EXPERIMENTAL
Intervention: Bone wax followed by colostomy paste
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bone wax alone (control)
Number of subjects: 56
Study: 36109026

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive behavioural therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Online COVID‐19 self‐help resources
Number of subjects: 140
Study: 33563370

Group type: EXPERIMENTAL
Intervention: Beacon model (GP-based integrated care)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Usual care (hospital outpatient departments)
Number of subjects: 5
Study: 33233981

Group type: EXPERIMENTAL
Intervention: Free eyeglasses
Number of subjects: 832

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 832
Study: 35575067

Group type: EXPERIMENTAL
Intervention: WP1066 at 8 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WP1066 at 1 mg/kg
Number of subjects: 8
Study: 34233923

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Number of subjects: 124

Group type: COMPARATOR
Intervention: High-flux hemodialysis
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hemodiafiltration and High-flux hemodialysis
Number of subjects: 124
Study: 35843545

Group type: EXPERIMENTAL
Intervention: Bipolar salpingectomy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional salpingectomy
Number of subjects: 51
Study: 33554636

Group type: EXPERIMENTAL
Intervention: Darolutamide and hormone therapy
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo and hormone therapy
Number of subjects: 1509
Study: 32273184

Group type: EXPERIMENTAL
Intervention: IPV-Al
Number of subjects: 800

Group type: COMPARATOR
Intervention: IPV
Number of subjects: 800
Study: 35227973

Group type: EXPERIMENTAL
Intervention: Group 1: Orientation messages recorded in a non-family member's voice (10 min), reading a daily newspaper, wearing an eye patch at night
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2: Orientation messages recorded in a family member's voice, reading a daily newspaper, wearing an eye patch at night
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: Standard nursing care
Number of subjects: 0
Study: 35051209

Group type: EXPERIMENTAL
Intervention: PC-6500 (0.1% GRFT in a carrageenan gel)
Number of subjects: 13

Group type: COMPARATOR
Intervention: PC-535 (matching CG placebo)
Number of subjects: 13
Study: 32918114

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with FVIII/FIX
Number of subjects: 53

Group type: COMPARATOR
Intervention: On-demand therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with FVIII/FIX in SHB
Number of subjects: 53

Group type: COMPARATOR
Intervention: On-demand therapy and hepatitis B and C
Number of subjects: 53

Group type: COMPARATOR
Intervention: Age, weight, and HIV positivity
Number of subjects: 53
Study: 34957859

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 33665997

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 15 mg/kg intravenous drops before operation incision at 10 min
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (100 ml normal saline intravenous drops before operation incision at 10 min)
Number of subjects: 34
Study: 35901201

Group type: EXPERIMENTAL
Intervention: Physical exertion (50 minutes of treadmill exercise in a heated room while wearing firefighter protective clothing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Total sleep deprivation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sleep disruption (three 60-minute awakenings)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rested control
Number of subjects: 24
Study: 34553603

Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, and dexamethasone (Isa-Kd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd) alone
Number of subjects: 0
Study: 36267873

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT-PTSD) for 14 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sertraline for 14 weeks
Number of subjects: 74
Study: 34516036

Group type: EXPERIMENTAL
Intervention: Learning Through Play (LTP) plus Culturally adapted Cognitive Behaviour Therapy (CaCBT)
Number of subjects: 0
Study: 35953335

Group type: EXPERIMENTAL
Intervention: Active ROM exercises (AE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Purposeful activity (PA)
Number of subjects: 35
Study: 33128939

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 65
Study: 32127870

Group type: EXPERIMENTAL
Intervention: Deep arm - AuraOnce™ laryngeal mask removed after attaining an end tidal minimum alveolar concentration of Isoflurane of 1.15%.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Awake arm - AuraOnce™ laryngeal mask removed on attaining an end tidal minimum alveolar concentration of Isoflurane of <0.5% and an appropriate response to command.
Number of subjects: 116
Study: 36442217

Group type: EXPERIMENTAL
Intervention: Premature infant oral motor intervention for five minutes twice a day along with routine care (n=16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine care (n=16)
Number of subjects: 32
Study: 33369019

Group type: EXPERIMENTAL
Intervention: Chicory long-chain inulin consumption for two months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32506744

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (3 Hz)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1 Hz)
Number of subjects: 45

Group type: COMPARATOR
Intervention: SHAM rTMS
Number of subjects: 45
Study: 34431240

Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg) after overnight fast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vonoprazan (20 mg) after high-fat breakfast
Number of subjects: 24
Study: 33654204

Group type: EXPERIMENTAL
Intervention: Midostaurin
Number of subjects: 717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study: 32241699

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 34403189

Group type: EXPERIMENTAL
Intervention: Self-care activities during COVID-19 pandemic
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resilience-building strategies
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Remote consultations with health professionals
Number of subjects: 26
Study: 32933335

Group type: EXPERIMENTAL
Intervention: Obinutuzumab-based immunochemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab-based immunochemotherapy
Number of subjects: 0
Study: 35460410

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention using validated tools to detect signs and symptoms of medicine-induced deterioration every 8 weeks over 12 months
Number of subjects: 248

Group type: COMPARATOR
Intervention: Usual care (Residential Medication Management Review) provided by accredited pharmacists
Number of subjects: 248
Study: 32039559

Group type: COMPARATOR
Intervention: CNI-based immunosuppressive regimen (tacrolimus)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-dose CNI plus costimulation blockade (belatacept) with intended CNI withdrawal
Number of subjects: 43
Study: 33902678

Group type: EXPERIMENTAL
Intervention: Breast milk enema
Number of subjects: 294

Group type: COMPARATOR
Intervention: Saline enema
Number of subjects: 294
Study: 33198679

Group type: COMPARATOR
Intervention: D&C
Number of subjects: 404

Group type: COMPARATOR
Intervention: EVA
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: MVA
Number of subjects: 404
Study: 34984815

Group type: EXPERIMENTAL
Intervention: Imeglimin 1000 mg twice daily
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 33499719

Group type: EXPERIMENTAL
Intervention: Parent Attitudes about Childhood Vaccines (PACV) survey
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Placebo survey
Number of subjects: 1705
Study: 32856707

Group type: EXPERIMENTAL
Intervention: Viral culture from respiratory samples
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seroconversion for IgM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Seroconversion for IgG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levels of inflammatory cytokines and chemokines
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 100
Study: 34753654

Group type: COMPARATOR
Intervention: HFOV
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HFOV-VG
Number of subjects: 58
Study: 33674671

Group type: EXPERIMENTAL
Intervention: Erythropoietin for neuroprotection
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control (no CP)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Whole transcriptome analysis
Number of subjects: 94
Study: 35546457

Group type: EXPERIMENTAL
Intervention: Melaleuca alternifolia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 33389005

Group type: EXPERIMENTAL
Intervention: Surgery for cosmetic reasons
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Surgery for functional reasons
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Groups with dissatisfaction (Groups 2, 4, and 6)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Expectation coverage rates
Number of subjects: 183
Study: 35701994

Group type: EXPERIMENTAL
Intervention: Robot-assisted THA (n = 45)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional THA (n = 48)
Number of subjects: 93
Study: 34180008

Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 271
Study: 35585718

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: duloxetine
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: pregabalin
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: mexiletine
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 402
Study: 32493359

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 264

Group type: COMPARATOR
Intervention: SG
Number of subjects: 264
Study: 35705234

Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nontracker group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 32119692

Group type: EXPERIMENTAL
Intervention: Priming positions language
Number of subjects: 0

Group type: COMPARATOR
Intervention: Priming interests language
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of gain frames and visual aids during bargaining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of loss frames and pro-self language
Number of subjects: 0
Study: 36496124

Group type: EXPERIMENTAL
Intervention: Continuous Regional Analgesia (CRA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Intravenous analgesia (Control)
Number of subjects: 76
Study: 33159633

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Tamoxifen monotherapy
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Sequential tamoxifen → letrozole
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Sequential letrozole → tamoxifen
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Tamoxifen → letrozole
Number of subjects: 6144

Group type: EXPERIMENTAL
Intervention: Letrozole → tamoxifen
Number of subjects: 6144

Group type: COMPARATOR
Intervention: Letrozole alone
Number of subjects: 6144
Study: 36195272

Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (average Danish diet)
Number of subjects: 18
Study: 34193518

Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (immobilisation, analgesics, spinal orthoses)
Number of subjects: 0
Study: 32700515

Group type: EXPERIMENTAL
Intervention: Sn-containing NaF dentifrice
Number of subjects: 60

Group type: COMPARATOR
Intervention: NaF control dentifrice
Number of subjects: 60
Study: 33515378

Group type: EXPERIMENTAL
Intervention: Acetic acid (AA) solution (0.005%) irrigated by a water pump
Number of subjects: 412

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 412
Study: 33295220

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine infusion (0.5 mg/kg bolus at induction, 0.25 mg/kg/h during surgery)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low-dose intravenous ketamine infusion
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 48
Study: 32894239

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training along with a combined physiotherapy program for six weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combined physiotherapy program for six weeks (Control group).
Number of subjects: 50
Study: 34774810

Group type: EXPERIMENTAL
Intervention: PBS+PLUS Intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist Treatment-as-usual
Number of subjects: 49
Study: 33180098

Group type: EXPERIMENTAL
Intervention: Vitamin B12 injection (1000 μg of cyanocobalamin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin B12 injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin B12 injection and Placebo
Number of subjects: 20
Study: 32898855

Group type: EXPERIMENTAL
Intervention: Serving fish sauce in a bowl with a spoon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Using a specially-designed spoon with a hole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-oriented nudges
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective-oriented nudges
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal condition (fish sauce served in a bottle)
Number of subjects: 0
Study: 35670659

Group type: EXPERIMENTAL
Intervention: Daily titration of iGlarLixi (1 unit/day)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Weekly titration of iGlarLixi (2 or 4 units/week)
Number of subjects: 265
Study: 33295063

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Exercise Group (EG) with ≥50% exercise attendance
Number of subjects: 84
Study: 33749539

Group type: EXPERIMENTAL
Intervention: CHO mouth rinse (6.4% maltodextrin = 1.6 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CAF mouth rinse (1.2% caffeine = 300 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO + CAF mouth rinse (6.4% + 1.2%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo mouth rinse (saccharin)
Number of subjects: 8
Study: 33723344

Group type: EXPERIMENTAL
Intervention: EBM THA stem
Number of subjects: 62

Group type: COMPARATOR
Intervention: BM THA stem
Number of subjects: 62
Study: 32310169

Group type: EXPERIMENTAL
Intervention: AC-1204 (caprylic triglyceride)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 33860732

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant (NZBC) powder (6 g/day for 7 days, with 138.6 mg anthocyanins)
Number of subjects: 14
Study: 32838616

Group type: EXPERIMENTAL
Intervention: OD-evening 80 mg aspirin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BID 40 mg aspirin
Number of subjects: 22

Group type: COMPARATOR
Intervention: OD-morning 80 mg aspirin
Number of subjects: 22
Study: 34995804

Group type: EXPERIMENTAL
Intervention: Carbohydrate loading with individualized supplemental insulin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Routine management (Control group)
Number of subjects: 63
Study: 33527072

Group type: EXPERIMENTAL
Intervention: Digital group intervention via Zoom (n = 64)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group (n = 18)
Number of subjects: 82
Study: 35751892

Group type: EXPERIMENTAL
Intervention: Liraglutide plus dapagliflozin (0.6 mg liraglutide and 5 mg dapagliflozin once a day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Liraglutide (0.6 mg)
Number of subjects: 125
Study: 32340150

Group type: EXPERIMENTAL
Intervention: Almond-Enriched Diet (AED)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Isocaloric Nut-Free Diet (NFD)
Number of subjects: 128
Study: 32007178

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme including muscle strengthening and proprioceptive re-education exercises
Number of subjects: 8
Study: 34773355

Group type: EXPERIMENTAL
Intervention: Uterine contractile activity during TOLAC
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cervical ripening with a Foley catheter
Number of subjects: 194

Group type: COMPARATOR
Intervention: Cervical dilatation <3 cm at admission
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Total uterine rupture incidence
Number of subjects: 194
Study: 32598387

Group type: EXPERIMENTAL
Intervention: Drospirenone (DRSP) 4 mg for 24 days followed by 4 days of placebo
Number of subjects: 858

Group type: COMPARATOR
Intervention: Desogestrel (DSG) 0.075 mg per day continuously
Number of subjects: 858
Study: 35870575

Group type: EXPERIMENTAL
Intervention: Immediate reduction to very low nicotine content (VLNC) cigarettes
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Gradual reduction to very low nicotine content (VLNC) cigarettes
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Normal nicotine research cigarettes (control)
Number of subjects: 1250
Study: 32165263

Group type: EXPERIMENTAL
Intervention: 6-week processing speed and attention (PS/A)‐targeted intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active control without PS/A
Number of subjects: 84
Study: 35679254

Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 33241607

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for blood pressure reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based intervention to treat substance use disorders
Number of subjects: 0
Study: 34958381

Group type: EXPERIMENTAL
Intervention: Brief counseling focused on pain management
Number of subjects: 0
Study: 33920981

Group type: EXPERIMENTAL
Intervention: Home-based physical training, nutritional, and social support intervention over 24 weeks
Number of subjects: 80
Study: 32664934

Group type: EXPERIMENTAL
Intervention: Internet-based partner notification through a mobile health (mHealth) service application (app)
Number of subjects: 6172

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 6172
Study: 35794811

Group type: EXPERIMENTAL
Intervention: Home-based vestibular rehabilitation therapy (Bal Ex)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hospital-based vestibular rehabilitation therapy (control)
Number of subjects: 30
Study: 34922713

Group type: EXPERIMENTAL
Intervention: Removable partial denture (RPD) for replacement of missing molars (n=79)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Shortened dental arch (SDA) without molar replacement (n=71)
Number of subjects: 150
Study: 32345707

Group type: EXPERIMENTAL
Intervention: Plan Well Guide (intervention group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 123
Study: 33790161

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m2) and Cisplatin (40 mg/m2) on days 1 and 15, and Bevacizumab (15 mg/kg) on day 1, repeated every 4 weeks
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Cisplatin plus Bevacizumab combination chemotherapy
Number of subjects: 6
Study: 33225971

Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 1.5 L/kg PBW/min (75–120 L/min)
Number of subjects: 12
Study: 34994945

Group type: EXPERIMENTAL
Intervention: Reach Plus
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Reach Plus Message
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Reach Plus Phone
Number of subjects: 161